MC

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

MC

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

MC

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

MC

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

MC

465.45

+2.5%↑

SANES

9.598

+4.29%↑

SAF

287.7

+2.42%↑

BBVA

18.415

+3.22%↑

BNP

83.36

+1.25%↑

Search

Viscofan SA

Chiusa

SettoreFinanza

56.9 -0.52

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

55.8

Massimo

57.4

Metriche Chiave

By Trading Economics

Entrata

12M

51M

Vendite

-3M

315M

P/E

Media del settore

16.886

54.048

EPS

1.115

Rendimento da dividendi

3.85

Margine di Profitto

16.276

Dipendenti

5,921

EBITDA

2.8M

71M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+27.18% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.85%

4.84%

Utili prossimi

23 apr 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

24M

2.7B

Apertura precedente

57.42

Chiusura precedente

56.9

Notizie sul Sentiment di mercato

By Acuity

40%

60%

116 / 441 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Viscofan SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 mar 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Discorsi di Mercato

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Discorsi di Mercato

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Discorsi di Mercato

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Discorsi di Mercato

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Principali Notizie su Eventi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Discorsi di Mercato
Utili
Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Viscofan SA Previsione

Obiettivo di Prezzo

By TipRanks

27.18% in crescita

Previsioni per 12 mesi

Media 73 EUR  27.18%

Alto 74 EUR

Basso 72 EUR

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Viscofan SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

63.6 / 64.4Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

116 / 441 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Viscofan SA

Viscofan, S.A., together with its subsidiaries, manufactures, produces, and distributes casings. The company offers cellulose casings for cooked, smoked, unsmoked, and dry-cured sausages. It provides collagen casings for processed and pre-cooked fried sausages, and dry-cured snacks, as well as provides collagen film cover for meat products under Total Control Net brand. In addition, the company offers fibrous casings under TITANIUM LINE brand; and transfer plastic casings under VISPICE brand. Further, it provides plastic casings, nanopack plastic films, and shrink bag related products. The company was incorporated in 1975 and is based in Tajonar, Spain.
help-icon Live chat